NCT03355976 2026-04-02BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasBrown UniversityPhase 2 Active not recruiting46 enrolled
NCT05544929 2026-01-06A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersNovartisPhase 1 Active not recruiting126 enrolled
NCT00565851 2025-12-30Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting1,052 enrolled 27 charts
NCT01582204 2025-08-05Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell CarcinomaMemorial Sloan Kettering Cancer CenterPhase NA Active not recruiting17 enrolled
NCT05032040 2025-02-07A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesXencor, Inc.Phase 2 Active not recruiting170 enrolled